3. Juni 2019
ASCO 2019: Breakfast Brief – Head and neck cancer
PD DDr. Sacha Rothschild, University Hospital Basel, comments on this year’s head and neck cancer studies, as well as lung cancer trials.
Inhalte im Video:
00:00KEYNOTE-048: Results support pembrolizumab and pembrolizumab + platinum + 5-FU for defined patients with recurrent metastatic HNSCC.
05:03Ado-trastuzumab emtansine is highly efficacious in patients with HER2 amplified salivary gland cancers.
06:24JIPANG: Pemetrexed/cisplatin shows similar efficacy compared to vinorelbine/cisplatin with better tolerability than adjuvant chemotherapy for completely resected stage II-IIIA non-squamous non-small-cell lung cancer.
07:38LCMC3: Neoadjuvant atezolizumab in resectable NSCLC was well tolerated, and pCR and major pathologic response rates are encouraging
08:48NEOSTAR: The study investigates neoadjuvant nivolumab or nivolumab plus ipilimumab on major pathologic response rates in resectable non-small-cell lung cancer